Cipla: Margins under pressure - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Cipla: Margins under pressure

Aug 4, 2003

Domestic pharma major, Cipla announced its first quarter FY04 results recently. While the company has posted a 13% increase in the topline, a marginal drop in the operating efficiency has restricted the company's bottomline growth at 11%. Let us briefly evaluate the performance of the company during 1QFY04.

(Rs m)1QFY031QFY04Change
Net Sales4,0304,54212.7%
Other Income486739.7%
Total expenditure3,2073,66914.4%
Operating Profit (EBDIT)8238746.2%
Operating Profit Margin (%)20.4%19.2% 
Interest210330.4%
Depreciation708825.0%
Profit before Tax7988435.6%
Tax192171-10.9%
Profit after Tax/(Loss)60667210.8%
Net profit margin (%)15.0%14.8% 
No. of Shares (m)60.060.0 
Earnings per share*40.444.8 
Current P/e ratio 18.0 
*(annualised)   

Cipla recorded a healthy growth in the net sales. However, a 25% rise in the raw material expense has affected the margins of the company. Raw material cost as a percentage of sales has gone up from 44% in 1QFY03 to 49% in the current quarter. This was primarily due to the change in the product mix of the company. Depreciation charges were also on the higher side on account of provision being made for the second phase of the Goa unit, which commenced commercial production during the quarter under review. Other income increased due to higher export benefits received during the current quarter. A drop in operating profit margins, sharp rise in the interest cost and a drop in the tax provisions on account of Sec 80I benefits have resulted in Cipla registering an 11% rise in net profits. Let us now study the revenue break up of the company.

Revenue break-up
(Rs m)1QFY031QFY04Change
Domestic 2,624 3,054 16.4%
Exports:   
Formulations 507 884 74.3%
Bulk drugs 882 562 -36.3%
Other operating income 16 42 161.1%
Total 4,030 4,542 12.7%

A close examination of the revenues indicates that although the export of formulations saw a steep rise, bulk drugs exports registered a sharp decline. This was on account of postponement of purchases by customers due to delay in patent rulings. On the domestic front, Cipla managed to outperform the industry with strong performance in the anti-biotic, anti-asthmatics and anti-hypertensives segments. The company has launched ‘Tiotropium’, a dry powder inhaler in the anti-asthma segment during the current quarter. Exports of formulations have seen a 74% growth. The growth was fuelled by good performance in the anti-AIDS segment.

Cipla has indicated that the export of CFC - free inhalers to Europe will commence as soon as the required regulatory approvals are received. However, the company has refused to give a time frame within which it expects to receive the requisite approval.

At Rs 807, Cipla is trading at a P/E of 18x its 1QFY04 earnings. Given the company’s ability to outperform in the domestic markets and the likely approval for export of CFC - free inhalers, the prospects of the company seem bright. However, delay in regulatory approval for products for which Cipla is the bulk drugs supplier and the uncertainty in respect of DPCO remain a cause for concern.

Equitymaster requests your view! Post a comment on "Cipla: Margins under pressure". Click here!

  

More Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

CIPLA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of CIPLA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Dec 7, 2021 (Close)

TRACK CIPLA

CIPLA - TEVA PHARMA COMPARISON

COMPARE CIPLA WITH

MARKET STATS